/ATE.TO
ATE.TO Stock - Antibe Therapeutics Inc.
Healthcare|Medical - DevicesTSX
$0.29+13.46%
+$0.04 (+13.46%) • Apr 8
58
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.12
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.32
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ATE.TO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.29 – $0.30
TARGET (TP)$0.34
STOP LOSS$0.27
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.19
52W High$1.23
52W Low$0.15
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $9.71M | $9.99M | $9.54M |
| Gross Profit | N/A | $-99,000 | $3.55M | $3.89M | $3.55M |
| Gross Margin | N/A | N/A | 36.5% | 38.9% | 37.2% |
| Operating Income | $-20,546,000 | $-25,529,000 | $-24,714,000 | $-18,917,000 | $-12,188,007 |
| Net Income | $-19,475,000 | $-25,055,000 | $-26,301,000 | $-19,342,000 | $-12,816,071 |
| Net Margin | N/A | N/A | -270.8% | -193.7% | -134.4% |
| EPS | $-0.37 | $-0.49 | $-0.71 | $-0.71 | $-0.60 |
Company Overview
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study. In addition, the company's products comprise ATB-352, which is in preclinical stage for acute pain. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ATE.TOBeat Rate
50%
Last 14 quarters
Avg Surprise
-19.6%
EPS vs Estimate
Beats / Misses
7/7
Last 12 quarters
Latest EPS
$-0.08
Q1 2024
EPS Surprise History
Q1 22
No data
Q2 22
+8.3%
$-0.11vs$-0.12
Q4 22
-9.1%
$-0.12vs$-0.11
Q1 23
+33.3%
$-0.08vs$-0.12
Q1 23
No data
Q3 23
-22.2%
$-0.11vs$-0.09
Q4 23
+16.7%
$-0.10vs$-0.12
Q1 24
+27.3%
$-0.08vs$-0.11
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2024 | Nov 11, 2024 | — | — | — | — |
Q3 2024 | Aug 12, 2024 | — | — | — | — |
Q1 2024 | Feb 14, 2024 | $-0.11 | $-0.08 | +27.3% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.12 | $-0.10 | +16.7% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.09 | $-0.11 | -22.2% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | — | $-0.07 | — | — |
Q1 2023 | Feb 15, 2023 | $-0.12 | $-0.08 | +33.3% | ✓ BEAT |
Q4 2022 | Nov 15, 2022 | $-0.11 | $-0.12 | -9.1% | ✗ MISS |
Q2 2022 | Jun 29, 2022 | $-0.12 | $-0.11 | +8.3% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | — | $-0.10 | — | — |
Q1 2022 | Feb 14, 2022 | $-0.14 | $-0.09 | +35.7% | ✓ BEAT |
Q4 2021 | Nov 16, 2021 | $-0.14 | $-0.17 | -21.4% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | $-0.15 | $-0.13 | +13.3% | ✓ BEAT |
Q1 2021 | Mar 31, 2021 | — | $-0.15 | — | — |
Q1 2021 | Feb 12, 2021 | $-0.19 | $-0.17 | +10.5% | ✓ BEAT |
Q4 2020 | Nov 13, 2020 | $-0.12 | $-0.20 | -66.7% | ✗ MISS |
Q3 2020 | Aug 24, 2020 | $-0.10 | $-0.20 | -100.0% | ✗ MISS |
Q1 2020 | Mar 31, 2020 | — | $-0.25 | — | — |
Q1 2020 | Feb 24, 2020 | $-0.10 | $-0.20 | -100.0% | ✗ MISS |
Q4 2019 | Nov 28, 2019 | $-0.10 | $-0.20 | -100.0% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about ATE.TO
What is ATE.TO's current stock price?
Antibe Therapeutics Inc. (ATE.TO) is currently trading at $0.29 per share. The stock has moved +13.46% today.
What is the analyst price target for ATE.TO?
No analyst price targets are currently available for this stock.
What sector is Antibe Therapeutics Inc. in?
Antibe Therapeutics Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the TSX exchange.
What is ATE.TO's market cap?
Antibe Therapeutics Inc. has a market capitalization of $0.02 billion, making it a small-cap company.
Does ATE.TO pay dividends?
No, Antibe Therapeutics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCHAL.CN
Chalice Brands Ltd.
$0.23
Mkt Cap: $0.0B
EXM.CN
EXMceuticals Inc.
$0.20
Mkt Cap: $0.0B
FAF.TO
Fire & Flower Holdings Corp.
$0.29
Mkt Cap: $0.0B
IMV.TO
IMV Inc.
$1.12
Mkt Cap: $0.0B
LXG.V
LexaGene Holdings Inc.
$0.10
Mkt Cap: $0.0B
MRV.TO
Nuvo Pharmaceuticals Inc.
$1.35
Mkt Cap: $0.0B
NUMI.TO
Numinus Wellness Inc.
$0.05
Mkt Cap: $0.0B
REUN.TO
Reunion Neuroscience Inc.
$1.42
Mkt Cap: $0.0B
RIV.CN
RIV Capital Inc.
$0.10
Mkt Cap: $0.0B
SGMD.V
Salona Global Medical Device Corporation
$0.22
Mkt Cap: $0.0B
Explore stocks similar to ATE.TO for comparison